A theme centered on acquiring Ganymed Pharmaceuticals and making it a wholly owned subsidiary, thereby acquiring and strengthening a cancer drug development platform that includes zolbetuximab (VYLOY). This also covers the discontinuation of zolbetuximab development for pancreatic adenocarcinoma after the acquisition.